BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37848935)

  • 21. ANGPTL4 accelerates KRAS
    Yan HH; Jung KH; Lee JE; Son MK; Fang Z; Park JH; Kim SJ; Kim JY; Lim JH; Hong SS
    Cancer Lett; 2021 Oct; 519():185-198. PubMed ID: 34311032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility.
    Knudsen ES; Balaji U; Mannakee B; Vail P; Eslinger C; Moxom C; Mansour J; Witkiewicz AK
    Gut; 2018 Mar; 67(3):508-520. PubMed ID: 28073890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mir34a constrains pancreatic carcinogenesis.
    Hidalgo-Sastre A; Lubeseder-Martellato C; Engleitner T; Steiger K; Zhong S; Desztics J; Öllinger R; Rad R; Schmid RM; Hermeking H; Siveke JT; von Figura G
    Sci Rep; 2020 Jun; 10(1):9654. PubMed ID: 32541781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Docking Protein p130Cas Regulates Acinar to Ductal Metaplasia During Pancreatic Adenocarcinoma Development and Pancreatitis.
    Costamagna A; Natalini D; Camacho Leal MDP; Simoni M; Gozzelino L; Cappello P; Novelli F; Ambrogio C; Defilippi P; Turco E; Giovannetti E; Hirsch E; Cabodi S; Martini M
    Gastroenterology; 2022 Apr; 162(4):1242-1255.e11. PubMed ID: 34922945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
    Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
    Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PYK2 Is Involved in Premalignant Acinar Cell Reprogramming and Pancreatic Ductal Adenocarcinoma Maintenance by Phosphorylating β-Catenin
    Gao C; Chen G; Zhang DH; Zhang J; Kuan SF; Hu W; Esni F; Gao X; Guan JL; Chu E; Hu J
    Cell Mol Gastroenterol Hepatol; 2019; 8(4):561-578. PubMed ID: 31330317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
    Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Krake S; Radefeldt M; Al-Ali R; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma.
    Huang J; Löhr JM; Nilsson M; Segersvärd R; Matsson H; Verbeke C; Heuchel R; Kere J; Iafrate AJ; Zheng Z; Ye W
    Clin Chem; 2015 Nov; 61(11):1408-16. PubMed ID: 26378065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma.
    Ramakrishnan G; Parajuli P; Singh P; Friend C; Hurwitz E; Prunier C; Razzaque MS; Xu K; Atfi A
    Cell Rep; 2022 Nov; 41(6):111623. PubMed ID: 36351408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1.
    Yan H; Yu CC; Fine SA; Youssof AL; Yang YR; Yan J; Karg DC; Cheung EC; Friedman RA; Ying H; Chen EI; Luo J; Miao Y; Qiu W; Su GH
    Oncogene; 2021 Dec; 40(50):6759-6771. PubMed ID: 34663879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.
    Zhao Z; Li X; Wang F; Xu Y; Liu S; Han Q; Yang Z; Huang W; Yin Z; Liu Q; Tan H; Ma T; Si S; Huang J; Yuan H; Li W; Liu R
    Cancer Med; 2023 May; 12(10):11672-11685. PubMed ID: 36999792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.
    Luo Y; Yang Y; Liu M; Wang D; Wang F; Bi Y; Ji J; Li S; Liu Y; Chen R; Huang H; Wang X; Swidnicka-Siergiejko AK; Janowitz T; Beyaz S; Wang G; Xu S; Bialkowska AB; Luo CK; Pin CL; Liang G; Lu X; Wu M; Shroyer KR; Wolff RA; Plunkett W; Ji B; Li Z; Li E; Li X; Yang VW; Logsdon CD; Abbruzzese JL; Lu W
    Gastroenterology; 2019 Nov; 157(5):1413-1428.e11. PubMed ID: 31352001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS.
    Zhao WG; Yu SN; Lu ZH; Ma YH; Gu YM; Chen J
    Carcinogenesis; 2010 Oct; 31(10):1726-33. PubMed ID: 20675343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zeb1 in Stromal Myofibroblasts Promotes
    Sangrador I; Molero X; Campbell F; Franch-Expósito S; Rovira-Rigau M; Samper E; Domínguez-Fraile M; Fillat C; Castells A; Vaquero EC
    Cancer Res; 2018 May; 78(10):2624-2637. PubMed ID: 29490942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.
    Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
    Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.
    Ling J; Kang Y; Zhao R; Xia Q; Lee DF; Chang Z; Li J; Peng B; Fleming JB; Wang H; Liu J; Lemischka IR; Hung MC; Chiao PJ
    Cancer Cell; 2012 Jan; 21(1):105-20. PubMed ID: 22264792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pancreatic adenocarcinoma with a germline PTEN p.Arg234Gln mutation.
    Uemura S; Matsubayashi H; Kiyozumi Y; Uesaka K; Yamamoto Y; Sasaki K; Abe M; Urakami K; Kusuhara M; Yamaguchi K
    Fam Cancer; 2018 Apr; 17(2):255-259. PubMed ID: 28755079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
    Zhang S; Chung WC; Xu K
    Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.